NCT03273712: Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

NCT03273712
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: SSTR+ (Somatostatin Receptor)
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 6 Months to 90 Years (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior peptide receptor radiotherapy (PRRT)
https://ClinicalTrials.gov/show/NCT03273712

Comments are closed.

Up ↑